JP2015516801A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015516801A5 JP2015516801A5 JP2014561381A JP2014561381A JP2015516801A5 JP 2015516801 A5 JP2015516801 A5 JP 2015516801A5 JP 2014561381 A JP2014561381 A JP 2014561381A JP 2014561381 A JP2014561381 A JP 2014561381A JP 2015516801 A5 JP2015516801 A5 JP 2015516801A5
- Authority
- JP
- Japan
- Prior art keywords
- binding
- seq
- cancer
- amino acid
- binding molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims 11
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 6
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 238000010494 dissociation reaction Methods 0.000 claims 2
- 230000005593 dissociations Effects 0.000 claims 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010025538 Malignant ascites Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims 1
- 206010061934 Salivary gland cancer Diseases 0.000 claims 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 210000002438 upper gastrointestinal tract Anatomy 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12159938 | 2012-03-16 | ||
| EP12159938.5 | 2012-03-16 | ||
| PCT/EP2013/054768 WO2013135588A1 (en) | 2012-03-16 | 2013-03-08 | Novel binding molecules with antitumoral activity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015516801A JP2015516801A (ja) | 2015-06-18 |
| JP2015516801A5 true JP2015516801A5 (cg-RX-API-DMAC7.html) | 2016-04-21 |
| JP6325463B2 JP6325463B2 (ja) | 2018-05-16 |
Family
ID=47844323
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014561381A Expired - Fee Related JP6325463B2 (ja) | 2012-03-16 | 2013-03-08 | 抗腫瘍活性を有する新規結合分子 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9593314B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2825197B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6325463B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20140135251A (cg-RX-API-DMAC7.html) |
| CN (1) | CN104284675B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2013231488B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112014022932A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2865597A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX354717B (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ629283A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2627185C1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013135588A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9956276B2 (en) | 2012-01-19 | 2018-05-01 | Duke University | Vaccines against antigens involved in therapy resistance and methods of using same |
| EP2752426A1 (en) | 2013-01-03 | 2014-07-09 | Covagen AG | Human serum albumin binding compounds and fusion proteins thereof |
| CA2931356A1 (en) | 2013-11-27 | 2015-06-04 | Zymeworks Inc. | Bispecific antigen-binding constructs targeting her2 |
| WO2015109012A1 (en) | 2014-01-14 | 2015-07-23 | Integrated Biotherapeutics, Inc. | Targeting immunological functions to the site of bacterial infections using cell wall targeting domains of bacteriolysins |
| EP3110429A4 (en) | 2014-02-27 | 2018-02-21 | Lycera Corporation | Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma & related therapeutic methods |
| ES2881602T3 (es) * | 2014-03-17 | 2021-11-30 | Mitsubishi Tanabe Pharma Corp | Conjugados de anticuerpo-fynómero |
| WO2015171558A2 (en) | 2014-05-05 | 2015-11-12 | Lycera Corporation | BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE |
| EP3140291A4 (en) | 2014-05-05 | 2018-01-10 | Lycera Corporation | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease |
| US20170196952A1 (en) | 2014-07-07 | 2017-07-13 | Duke University | Vaccines against an oncogenic isoform of esr1 and methods of using the same |
| WO2016007499A1 (en) | 2014-07-07 | 2016-01-14 | Duke University | Vaccines against an oncogenic isoform of her2 (erbb2) and methods of using the same |
| JP6872482B2 (ja) | 2014-11-27 | 2021-05-19 | ザイムワークス，インコーポレイテッド | Ｈｅｒ２を標的とする二重特異性抗原結合性構築物の使用方法 |
| JP2018515491A (ja) | 2015-05-05 | 2018-06-14 | リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ | ＲＯＲγの作動薬及び疾患の療法として使用するジヒドロ−２Ｈ−ベンゾ［ｂ］［１，４］オキサジンスルホンアミド及び関連化合物 |
| MX2017016134A (es) | 2015-06-11 | 2018-08-15 | Lycera Corp | Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad. |
| FI126633B (en) | 2015-07-10 | 2017-03-15 | Next Biomed Therapies Oy | Method for the preparation of a library of derivatives of the SH3 domain of recombinant nephrocystin (NPHP1) |
| US11253580B2 (en) | 2016-01-07 | 2022-02-22 | Duke University | Cancer vaccines and methods of delivery |
| US11224665B2 (en) | 2016-10-05 | 2022-01-18 | Duke University | Mitochondrial antiviral signaling (MAVS) protein compositions and methods of using the same |
| US10487143B2 (en) | 2016-10-05 | 2019-11-26 | Duke University | Vaccines against HER3 antigens and methods of using the same |
| KR102221364B1 (ko) | 2016-11-21 | 2021-03-04 | 쿠레아브 게엠베하 | 항-gp73 항체 및 면역접합체 |
| US10722589B2 (en) * | 2017-04-03 | 2020-07-28 | Covagen Ag | FGFR3 binding molecules |
| US20190153096A1 (en) | 2017-10-02 | 2019-05-23 | Covagen Ag | Cd3/cd33 bispecific binding molecules |
| US20190100587A1 (en) | 2017-10-02 | 2019-04-04 | Covagen Ag | IgG1 Fc MUTANTS WITH ABLATED EFFECTOR FUNCTIONS |
| CA3086879A1 (en) | 2018-01-05 | 2019-07-11 | Ac Immune Sa | Misfolded tdp-43 binding molecules |
| JP7350756B2 (ja) | 2018-02-14 | 2023-09-26 | アバ セラピューティクス アーゲー | 抗ヒトｐｄ－ｌ２抗体 |
| RU2018111298A (ru) * | 2018-03-29 | 2019-10-01 | Закрытое Акционерное Общество "Биокад" | Биспецифическое антитело, которое специфично связывается с IV и II cубдоменами внеклеточного домена HER2 человека |
| EP3956027A1 (en) | 2019-04-18 | 2022-02-23 | AC Immune SA | Novel molecules for therapy and diagnosis |
| JP2022533432A (ja) | 2019-05-23 | 2022-07-22 | エイシー イミューン ソシエテ アノニム | 抗ｔｄｐ－４３結合分子およびその使用 |
| WO2020254540A1 (en) | 2019-06-18 | 2020-12-24 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Site-specific, kinetically inert conjugation of labels and/or carriers to target molecules such as his-tagged proteins via metal complex reagents |
| EP4061830A1 (en) | 2019-11-20 | 2022-09-28 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Archaeal peptide recombinase - a novel peptide ligating enzyme |
| US20210188990A1 (en) | 2019-12-11 | 2021-06-24 | Cilag Gmbh International | Multispecific binding molecules comprising ltbr and edb binding domains and uses thereof |
| US20240002430A1 (en) | 2020-08-07 | 2024-01-04 | Hoffman-La Roche Inc. | Method for producing protein compositions |
| CN116615452A (zh) | 2020-08-14 | 2023-08-18 | Ac免疫有限公司 | 人源化抗tdp-43结合分子及其用途 |
| WO2022043517A2 (en) | 2020-08-27 | 2022-03-03 | Cureab Gmbh | Anti-golph2 antibodies for macrophage and dendritic cell differentiation |
| WO2022079297A1 (en) | 2020-10-16 | 2022-04-21 | Ac Immune Sa | Antibodies binding to alpha-synuclein for therapy and diagnosis |
| WO2023044483A2 (en) | 2021-09-20 | 2023-03-23 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
| US20250320284A1 (en) | 2021-11-16 | 2025-10-16 | Ac Immune Sa | Novel Molecules for Therapy and Diagnosis |
| WO2023092004A1 (en) | 2021-11-17 | 2023-05-25 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| AU2023221539A1 (en) | 2022-02-16 | 2024-08-22 | Ac Immune Sa | Humanized anti-tdp-43 binding molecules and uses thereof |
| CA3246990A1 (en) | 2022-04-08 | 2023-10-12 | Ac Immune Sa | ANTI-TDP-43 BINDING MOLECULES |
| US20250295809A1 (en) | 2022-05-13 | 2025-09-25 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
| CN120917043A (zh) | 2023-03-08 | 2025-11-07 | Ac免疫有限公司 | 抗tdp-43结合分子及其用途 |
| WO2025122634A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| WO2025221728A2 (en) | 2024-04-15 | 2025-10-23 | Janssen Biotech, Inc. | Ltbr binding molecules and uses thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6184205B1 (en) | 1994-07-22 | 2001-02-06 | University Of North Carolina At Chapel Hill | GRB2 SH3 binding peptides and methods of isolating and using same |
| US5922845A (en) | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
| US7332585B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The California University | Bispecific single chain Fv antibody molecules and methods of use thereof |
| GT200500155A (es) * | 2004-06-16 | 2006-05-15 | Terapia del càncer resistente al platino | |
| KR20150140417A (ko) * | 2004-07-22 | 2015-12-15 | 제넨테크, 인크. | Ｈｅｒ２ 항체 조성물 |
| CA2577405A1 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Anti-fc-gamma riib receptor antibody and uses therefor |
| EP1892248A1 (en) * | 2006-08-21 | 2008-02-27 | Eidgenössische Technische Hochschule Zürich | Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase |
| US9513296B2 (en) | 2006-08-21 | 2016-12-06 | Eidgenoessische Technische Hochschule Zurich | Specific and high affinity binding proteins comprising modified SH3 domains of Fyn kinase |
| AU2008282218A1 (en) | 2007-07-31 | 2009-02-05 | Medimmune, Llc | Multispecific epitope binding proteins and uses thereof |
| MY188455A (en) * | 2007-10-19 | 2021-12-09 | Genentech Inc | Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates |
| WO2011020033A2 (en) * | 2009-08-13 | 2011-02-17 | Massachusetts Institute Of Technology | Engineered proteins including mutant fibronectin domains |
| US9376477B2 (en) * | 2009-08-27 | 2016-06-28 | Covagen Ag | IL-17 binding compounds and medical uses thereof |
| CN107337734A (zh) * | 2009-12-04 | 2017-11-10 | 弗·哈夫曼-拉罗切有限公司 | 多特异性抗体、抗体类似物、组合物和方法 |
| WO2011073214A2 (en) * | 2009-12-14 | 2011-06-23 | Scil Proteins Gmbh | A method for identifying hetero-multimeric modified ubiquitin proteins with binding capability to ligands |
| CN107253992B (zh) * | 2010-05-27 | 2022-03-11 | 根马布股份公司 | 针对her2的单克隆抗体 |
| WO2012009705A1 (en) * | 2010-07-15 | 2012-01-19 | Zyngenia, Inc. | Ang-2 binding complexes and uses thereof |
-
2013
- 2013-03-08 CA CA2865597A patent/CA2865597A1/en not_active Abandoned
- 2013-03-08 BR BR112014022932A patent/BR112014022932A2/pt not_active Application Discontinuation
- 2013-03-08 AU AU2013231488A patent/AU2013231488B2/en not_active Ceased
- 2013-03-08 KR KR1020147029084A patent/KR20140135251A/ko not_active Ceased
- 2013-03-08 WO PCT/EP2013/054768 patent/WO2013135588A1/en not_active Ceased
- 2013-03-08 NZ NZ629283A patent/NZ629283A/en not_active IP Right Cessation
- 2013-03-08 MX MX2014011066A patent/MX354717B/es active IP Right Grant
- 2013-03-08 RU RU2014141598A patent/RU2627185C1/ru not_active IP Right Cessation
- 2013-03-08 EP EP13708424.0A patent/EP2825197B1/en not_active Not-in-force
- 2013-03-08 CN CN201380014237.9A patent/CN104284675B/zh not_active Expired - Fee Related
- 2013-03-08 US US14/385,729 patent/US9593314B2/en not_active Expired - Fee Related
- 2013-03-08 JP JP2014561381A patent/JP6325463B2/ja not_active Expired - Fee Related
-
2017
- 2017-03-09 US US15/454,769 patent/US20170281768A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015516801A5 (cg-RX-API-DMAC7.html) | ||
| JP2016516789A5 (cg-RX-API-DMAC7.html) | ||
| NZ708182A (en) | Bispecific t cell activating antigen binding molecules | |
| JP2013166763A5 (cg-RX-API-DMAC7.html) | ||
| FI3348571T3 (fi) | Yksidomeeninen vasta-aine ohjelmoitu solukuolema -ligandille (pd-l1) ja siitä peräisin oleva proteiini | |
| MX2014011066A (es) | Moleculas de union novedosas con actividad antitumoral. | |
| JP2020506971A5 (cg-RX-API-DMAC7.html) | ||
| IL256871B2 (en) | Constructs for bispecific antibodies binding dll3 and cd3 and uses thereof | |
| JP2017140051A5 (cg-RX-API-DMAC7.html) | ||
| RU2022102446A (ru) | Биспецифические связывающие белки и пути их применения | |
| JP2014088414A5 (cg-RX-API-DMAC7.html) | ||
| HRP20192347T1 (hr) | Antitijela prema klaudinu 18.2 koja su korisna u dijagnozi tumora | |
| RU2017108203A (ru) | Слитые белки sirp-альфа с иммуноглобулином | |
| JP2019535234A5 (cg-RX-API-DMAC7.html) | ||
| RU2019118257A (ru) | Анти-cd47 антитела и способы их применения | |
| JP2014518615A5 (cg-RX-API-DMAC7.html) | ||
| JP2015119705A5 (cg-RX-API-DMAC7.html) | ||
| RU2014109557A (ru) | Антитела, не содержащие fc-фрагмента, включающие два fab-фрагмента, и способы их применения | |
| RU2015144098A (ru) | Четырехвалентные биспецифические антитела | |
| MX2010004910A (es) | Anticuerpos monoclonales recombinantes y antigenos correspondientes para canceres colonico y pancreatico. | |
| FI3227342T4 (fi) | Proteiininen heterodimeeri ja sen käyttö | |
| JP2011510632A5 (cg-RX-API-DMAC7.html) | ||
| JP2017525698A5 (cg-RX-API-DMAC7.html) | ||
| HRP20211788T1 (hr) | Postupak i pripravci za poboljšanje anti-tumorskog efektorskog funkcioniranja t stanica | |
| JP2013540696A5 (cg-RX-API-DMAC7.html) |